Table 3.
Serum levels of inflammatory cytokines
| n | TNF‐α | IFN‐γ | MCP‐1 | IL‐10 | IL‐6 | |
|---|---|---|---|---|---|---|
| One booster | ||||||
| B+I+ | 3 | 15.9 ± 3.8 | 4.9 ± 0.8 | 31.5 ± 2.4 | 2.8 ± 4.8 | 2.9 ± 1.9 |
| B+I− | 3 | 14.7 ± 2.8 | 4.2 ± 5.1 | 43.3 ± 9.3 | 0.0 ± 0.0 | 2.3 ± 0.4 |
| B−I+ | 3 | 9.8 ± 1.4 | 3.1 ± 3.0 | 29.1 ± 4.4 | 0.0 ± 0.0 | 1.8 ± 1.7 |
| Four boosters | ||||||
| B+I+ | 5 | 27.4 ± 22.4 a | 10.7 ± 7.6 a | 61.3 ± 27.7 a | 2.7 ± 6.0 | 6.6 ± 2.9 |
| B+I− | 5 | 17.3 ± 3.0 a | 8.4 ± 3.9 a | 51.0 ± 9.1 a | 1.3 ± 1.8 | 6.8 ± 1.8 |
| B−I+ | 5 | 11.4 ± 4.9 | 2.7 ± 1.1 | 42.4 ± 4.6 | 2.2 ± 3.0 | 6.2 ± 2.9 |
| B−I− | 5 | 8.1 ± 1.3 | 0.7 ± 0.9 | 38.1 ± 5.8 | 2.7 ± 4.0 | 5.8 ± 1.4 |
| Anti‐PrxII | ||||||
| B+P+ | 5 | 25.5 ± 13.5 a | 9.5 ± 2.2 b | 83.0 ± 9.8 a | 0.0 ± 0.0 | 5.7 ± 1.2 |
| B+P− | 5 | 18.2 ± 3.7 a | 5.9 ± 1.7 a | 67.8 ± 11.0 a | 0.9 ± 2.0 | 5.5 ± 1.2 |
| B−P+ | 5 | 9.1 ± 2.2 | 1.0 ± 1.1 | 48.1 ± 9.9 | 0.4 ± 0.8 | 4.8 ± 0.9 |
| B−P− | 5 | 7.3 ± 0.6 | 1.3 ± 0.8 | 38.1 ± 5.7 | 0.0 ± 0.0 | 3.9 ± 1.4 |
Data are expressed as mean ± SD (pg mL−1).
One booster: an experimental primary inoculation followed by one cMI inoculation or its substitute.
Four boosters: an experimental primary inoculation followed by four cMI inoculations or their substitutes.
Anti‐PrxII: an experimental primary inoculation followed by administration of antiperoxiredoxin II antibody or its substitute.
B+, BCG administered; B−, saline administered as a substitute for BCG; I+, cMI administered; I−, saline administered as a substitute for cMI; P+, anti‐peroxiredoxin II antibody administered; P−, saline administered as a substitute for antiperoxiredoxin II antibody.
Significant difference from control (B−P−).
Significant difference from control and B+I− group.